EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection

Noriko Morimoto iD, Noriomi Suzuki, Kanako Imamura, Tomohiro Saikawa, Naoto Miyoshi

Laryngoscope Investigative Otolaryngology · 2026-04 · 11 (2)

DOI: 10.1002/lio2.70386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 30.03.2026. Verfasst von Noriko Morimoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology National Center for Child Health and Development Tokyo Japan. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to evaluate the long‐term auditory outcomes of early antiviral therapy with valganciclovir (VGCV) in children with congenital cytomegalovirus (cCMV) infection, regardless of initial symptomatology.

Methods

This retrospective cohort study included 56 pediatric patients (112 ears) diagnosed with cCMV infection between 2004 and 2022 at our institution. The participants were divided into those who received (treated group, n = 19) and did not receive (untreated group, n = 37) VGCV or ganciclovir therapy. Audiological assessments were conducted over a minimum 2‐year follow‐up period (range, 2–15 years). Furthermore, hearing thresholds were evaluated longitudinally, with a decline of ≥ 10 dB being defined as significant. The primary outcomes were hearing loss progression and age at onset.

Results

At the final follow‐up, there were no significant between‐group differences in the prevalence or severity of hearing loss. However, fewer ears showed significant hearing deterioration in the treated group (26%) than in the untreated group (41%, p < 0.01). Furthermore, the magnitude of hearing decline was smaller in the treated group (35.0 ± 13.8 dB) than in the untreated group (67.4 ± 19.2 dB) ( p < 0.002). Hearing loss in treated patients stabilized by the age of 3 years; in contrast, untreated patients experienced multiple deterioration episodes even after this age.

Conclusions

Early VGCV treatment may help stabilize hearing and reduce long‐term hearing deterioration in children with cCMV infections. This highlights the importance of early intervention and hearing surveillance, especially in untreated individuals. Level of Evidence 4

Schlagwörter

Stichwörter der Autor:innen

antiviral therapycongenital cytomegaloviruslong‐term outcomespediatric hearing lossvalganciclovir

Autor:innen und Institutionen

  • Department of Otolaryngology National Center for Child Health and Development Tokyo Japan.

ORCID-Profile: Noriko Morimoto

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Morimoto, N., Suzuki, N., Imamura, K., Saikawa, T., & Miyoshi, N. (2026). Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection. Laryngoscope Investigative Otolaryngology, 11(2). https://doi.org/10.1002/lio2.70386

Vancouver

Morimoto N, Suzuki N, Imamura K, Saikawa T, Miyoshi N. Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection. Laryngoscope Investigative Otolaryngology. 2026;11(2). doi:10.1002/lio2.70386

BibTeX
@article{Morimoto2026,
  author = {Morimoto, Noriko and Suzuki, Noriomi and Imamura, Kanako and Saikawa, Tomohiro and Miyoshi, Naoto},
  title = {Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {2},
  doi = {10.1002/lio2.70386}
}
Kostenlos starten →